Yale Catriona

Chief Development Officer Yale Catriona sold 49,074 shares for $2,734,212.41 at AKRO on 2025-01-27, reducing holdings by 33.9%

Yale Catriona executed three separate open-market sales totaling 49,074 shares for $2,734,212.41 on 2025-01-27 at prices ranging from $55.15 to $57.01, disposing of 33.9% of prior holdings and leaving 95,648 shares. The sales occurred near the 52-week high of $55.36, with the blended average price of $55.72 representing a 2.3% discount to that peak. In prior trades at AKRO, the insider's two prior measurable sales (2023-06-23) both produced negative 90-day returns of -15.0% and -13.9%, establishing a 100% well-timed rate at this ticker over the observation window. Against this backdrop, the company remains unprofitable (net income $-72,705,000.00 for the most recent full fiscal year), which compounds the significance of a large reduction in insider share ownership by a senior executive.

CDO Yale Catriona sold 53,590 shares at avg $56.25 (−35.9% of holdings) on 2025-01-27 for $3,014,216.41 total

Yale Catriona, Chief Development Officer at Akero Therapeutics, executed 3 separate sales totaling 53,590 shares for $3,014,216.41 on 2025-01-27, reducing her holdings from 149,238 shares to 95,648 shares (a −35.9% reduction). The blended average sale price of $56.25 is near the 52-week high of $55.36, occurring at a point when the stock is up +94.4% over the prior 30 days and +67.3% over the prior 90 days, reflecting a sharp recent rally. Across the insider's cross-ticker history, her prior 7 sells achieved a 100.00% well-timed rate at the 90-day mark, and at AKRO specifically, both prior measurable sales in 2023 resulted in negative 90-day returns, suggesting a pattern of selling ahead of declines. The company posted a net loss of $72,705,000.00 and remains unprofitable, providing a backdrop of operational challenge against which a substantial insider reduction in holdings warrants investor attention to forward guidance and competitive position.